Study Evaluating the Safety, in Terms of HBV Virological Control at 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected With the HIV-1 and HBV Viruses
Conditions: HIV Infections; HBV Coinfection Interventions: Drug: TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI; Drug: Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR) Sponsors: ANRS, Emerging Infectious Diseases Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs
Conditions: Hepatocellular Carcinoma Interventions: Diagnostic Test: General Evaluation Score (GES) Sponsors: Egyptian Liver Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials
Evolution of the Clinical, Immuno-virological and Aging Trajectory of Patients Living With HIV
Conditions: HIV Infections Sponsors: Centre de Recherches et d ' Etude sur la Pathologie Tropicale et le Sida Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial
This study is a randomized, open-label trial. A total of 240 participants will be randomized 1:1 into groups receiving TDF or entecavir monotherapy. The two groups will be compared in terms of recurrence-free and overall survival at 1, 3, and 5 years after surgery; adverse events; virological response; rate of alanine transaminase normalization; and seroreactivity at 24 and 48 weeks after surgery.DiscussionThis study will compare long-term survival between patients with HBV-associated HCC who receive TDF or entecavir monotherapy. Numerous outcomes related to prognosis will be analyzed and compared in this study.Trial re...
Source: Trials - January 5, 2024 Category: Research Source Type: clinical trials
Duration of Dual Antiretroviral Therapy in Virologically Suppressed People Living With HIV and Factors Associated With Switching to Tritherapy : a Real-life Cohort
Conditions: HIV Infections Interventions: Other: dual therapy Sponsors: Tourcoing Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV
Conditions: Monkeypox; HIV Infections; AIDS Intervention: Sponsor: Centers for Disease Control and Prevention Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
Condition: HIV Infections Interventions: Biological: VH3810109; Drug: Cabotegravir; Drug: Standard of care (SOC); Biological: rHuPH20 Sponsor: ViiV Healthcare Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 18, 2023 Category: Research Source Type: clinical trials
